The Latest Breaking News from FDA

Strawberries, leafy greens, grapes and green beans are just a few items on the EWG's annual list

This change follows the recent FDA approval of the weight-loss drug for preventing heart attack and stroke in people with overweight or obesity.

The Supreme Court hears arguments Tuesday in a challenge that could limit access to a widely used drug for medication abortions.

The market offers many alternatives to bad desserts. We don’t need the FDA to step in.

The pharmaceutical industry is rapidly expanding, fueled by continued R&D efforts leading to the discovery of new drugs and therapies, biotechnology innovations, and growing medical needs. Thus, let’s take a look at pharma gems Pacira BioSciences (PCRX), Calliditas Therapeutics (CALT), and Astellas Pharma (ALPMY) poised for breakthroughs. Read more….

In the name of safety, politicians did many things that diminished our lives—without making us safer.

Revamping cancer classification to focus on molecular characteristics over organ of origin can result in more effective and timely treatment, a group of doctors has said.

Lawsuit against Gilead Sciences raises concerns about innovation impact in drug development and potential implications on future product development.

Top pharmaceutical companies purchased electoral bonds amidst regulatory scrutiny, including Hetero, MSN, Divi's, Intas, Lupin, Mankind, Micro Labs, and Natco.

That's the highest number in more than a decade, according to new research. Medication abortion made up a larger share of the total than in 2020.

The pharma industry is well-positioned to remain buoyed, owing to the rise in chronic diseases, a growing elderly population, and the integration of advanced technologies. Given this backdrop, quality pharma stocks Bristol-Myers Squibb Company (BMY), Johnson & Johnson (JNJ), Novartis AG (NVS), and Merck & Co. (MRK), making waves in…